UBRELVY—
THE ANYTIME, ANYWHERE MIGRAINE MEDICINETM FOR QUICK PAIN RELIEF1-4*

*UBRELVY is not indicated for the preventive treatment of migraine. Migraine pain relief—61.7% (UBRELVY 50 mg) vs 48.7% (placebo) at 2 hours.1,2

EfficacyResult

EFFICACY STORY

PatientProfile

PATIENT PROFILES

LearnMore

LEARN MORE
1logo 1logo 1logo
†As of 01/21

1ST IN ITS CLASS.‡
1ST IN MARKET.
IN THE 1ST YEAR.

†As of 01/21

Most prescribed in its class‡ by Neurologists, PCPs, NPs, and PAs1

• Over 33,000 HCPs have prescribed UBRELVY more than 400,000 times1,5

• More than 160,000 patients treated with UBRELVY1

• 90% of commercial lives covered1

– As of 9/20. Prior Authorization and other restrictions may apply.

†Based on retail and non-retail monthly prescription data from IQVIA on a 6-month rolling basis as of 01/21. ‡gepants for the acute treatment of migraine.

UBRELVY EFFICACY STORY

STUDY DESIGN

SEE THE STUDY DESIGN modalicon
reliefchartthumbnailreliefchartthumbnailreliefchartthumbnail

UBRELVY QUICKLY RELIEVES MIGRAINE PAIN WITH JUST ONE DOSE1,2

61.7% (UBRELVY 50 mg) vs 48.7% (placebo) at 2 hours

EXPAND TO SEE FULL RESULTS modalicon
eliminationchartthumbnaileliminationchartthumbnaileliminationchartthumbnail

ELIMINATION OF MIGRAINE
HEADACHE PAIN WITH ONE DOSE1,3,4

20.5% (UBRELVY 50 mg) vs 13% (placebo) at 2 hours

EXPAND TO SEE FULL RESULTS modalicon
functionchartthumbnailfunctionchartthumbnailfunctionchartthumbnail

UBRELVY— FUNCTIONAL IMPROVEMENT DATA WITH JUST ONE DOSE1

64% (UBRELVY 100 mg) vs 54% (placebo) at 2 hours

EXPAND TO SEE FULL RESULTS modalicon
waves waves waves

EVERY MIGRAINE PATIENT
IS DIFFERENT

Consider UBRELVY for a range of patient types.

carouseltopcurve
carouseltopcurve
carouselbottomcurve
carouselbottomcurve
dosingphoto dosingphoto dosingphoto
Tablets are not actual size.
dosingicon

UBRELVY IS AVAILABLE IN BOTH 50 MG AND 100 MG TABLETS1

videotopcurveblue
videotopcurveblue
WATCH TO LEARN MORE
PatientStoryvideothumbnail
playbuttondefault playbuttonhover UBRELVY Patient Story 01:56
SerenaCommercialvideothumbnail
playbuttondefault playbuttonhover Serena Williams Hits Back Against Migraine with UBRELVY 00:30
videobottomcurveblue
videobottomcurveblue

RESOURCE CENTER

Select a resource below to learn more about UBRELVY.

DosingCardDosingCardDosingCard

spanish

DOSING FORM downloadicon"
IMPORTANT SAFETY INFORMATION
Contraindication

Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions

• Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.

• Dose modifications are recommended when using the following:
‐ Moderate or weak CYP3A4 inhibitors and inducers ‐ BCRP and/or P-gp only inhibitors

Dosage and Administration

• The recommended dose is 50 mg or 100 mg taken orally, as needed.

• If needed, a second dose may be administered at least 2 hours after the initial dose.

• The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

• Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.

• Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

REFERENCES

1. Data on file. Allergan. 2. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2020. 3. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241. 4. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain from the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. 5. IQVIA RAPID NPA Weekly Audit. Weekly audit for acute migraine Rx: week of 12/4/2020. 6. Dodick DW, Goadsby PJ, Lu K, Jakata A, Szegedi A, Trugman JM. Ubrogepant achieves early pain relief for the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster P103. 7. Lipton RB, Ailani J, Hutchinson S, et al. Efficacy is maintained with long-term intermittent use of ubrogepant for the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster P135.

More
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindication

Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions

• Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.

• Dose modifications are recommended when using the following:
‐ Moderate or weak CYP3A4 inhibitors and inducers ‐ BCRP and/or P-gp only inhibitors

Dosage and Administration

• The recommended dose is 50 mg or 100 mg taken orally, as needed.

• If needed, a second dose may be administered at least 2 hours after the initial dose.

• The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

• Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.

• Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

>